archive-com.com » COM » E » ENDEAVOURVISION.COM

Total: 462

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Recent news: CeQur SA Closes $27 Million Series B Financing
    of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Funding Will Support Broad Scale Commercialization of CeQur PaQ Insulin Delivery Device HORW Switzerland Sept 9 2013 CeQur SA a company focused on the development and commercialization of simple insulin delivery devices announced the closing of a 27 million dollar Series B financing The financing was led by two new private investors with the participation of all current shareholders and will support manufacturing scale up for the CeQur PaQ simple insulin delivery device which received CE Mark approval in November 2012 Proceeds from this financing round will also be used to fund activities related to United States regulatory approval In a study involving people with type 2 diabetes completed last year PaQ safely and

    Original URL path: http://www.endeavourvision.com/news-n198-c0-s22-CeQur+SA+Closes+%2427+Million+Series+B+F.htm (2016-04-25)
    Open archived version from archive


  • Recent news: BIND Doses First Patient in a Phase 2 Clinical Study of BIND-014 in Prostate Cancer
    its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Second of Two Phase 2 Clinical Studies Initiated with BIND 014 in 2013 Cambridge MA August 19 2013 BIND Therapeutics a clinical stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins announced today that it has dosed the first patient in a Phase 2 clinical trial to assess the safety and efficacy of BIND 014 a PSMA targeted Accurin containing docetaxel as first line therapy in patients with chemotherapy naïve metastatic castrate resistant prostate cancer While treatment options for metastatic castrate resistant prostate cancer have advanced in recent years primarily due to an increased understanding of androgen receptor biology a significant unmet need remains for patients who fail hormonal agents said Gregory Berk

    Original URL path: http://www.endeavourvision.com/news-n197-c0-s22-BIND+Doses+First+Patient+in+a+Phase+2+Cl.htm (2016-04-25)
    Open archived version from archive

  • Recent news: BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering
    September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Cambridge MA August 12 2013 BIND Therapeutics a clinical stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins announced today that it has filed a registration statement on Form S 1 with the U S Securities and Exchange Commission SEC relating to a proposed initial public offering of shares of its common stock All shares of the common stock to be sold in the offering will be offered by BIND The number of shares to be offered and the price range for the offering have not yet been determined Credit Suisse USA LLC and Cowen and Company LLC are acting as joint book running managers for the offering Stifel Nicolaus Company Incorporated and JMP Securities LLC are acting as co

    Original URL path: http://www.endeavourvision.com/news-n194-c0-s22-BIND+Therapeutics+Files+Registration+Sta.htm (2016-04-25)
    Open archived version from archive

  • Recent news: Symetis announces successful, first time implantation of i ts ACURATE TA™ and ACURATE TF™ TAVI systems in Japan
    Molecular Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Procedures performed at Osaka University Hospital Four patients successfully treated in initial feasibility study Results to support PMDA filing ECUBLENS SWITZERLAND August 12 2013 Symetis Inc a privately owned Swiss company focused on transcatheter aortic valve implantation TAVI systems announced that its ACURATE TA tm and ACURATE TF tm TAVI systems were used to successfully treat patients at the Department of Cardiovascular Surgery of the Osaka University Graduate School of Medicine These procedures were performed as part of a feasibility study being conducted under the leadership of Professor Yoshiki Sawa The four patients were treated by Professor Toru Kuratani with two patients receiving a transapical ACURATE TA tm valve and

    Original URL path: http://www.endeavourvision.com/news-n195-c0-s22-Symetis+announces+successful%2C+first+ti.htm (2016-04-25)
    Open archived version from archive

  • Recent news: BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row
    Accurin Nanomedicines for Oncology October 8 2014 Molecular Partners sets the price range for its IPO at CHF 28 to CHF 35 per share First trading day expected for 22 October 2014 October 6 2014 Sophia Genetics Adds Cystic Fibrosis Analysis to Clinical Bioinformatics Portfolio September 23 2014 Molecular Partners launches IPO on SIX Swiss Exchange September 22 2014 FierceBiotech names Molecular Partners as one of its Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs MIT s Technology Review Unveils 2011 TR50 List of the World s Most Innovative Companies more Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling

    Original URL path: http://www.endeavourvision.com/news-n108-c0-s22-BIND+Biosciences+named+one+of+MIT%27s+Te.htm (2016-04-25)
    Open archived version from archive

  • Recent news: CeQur SA names Robert O'Holla EVP for Regulatory Affairs
    Fierce 15 Biotech Companies of 2014 September 12 2014 Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo and Launches Product With First Commercial Implantations September 2 2014 Sophia Genetics Becomes the First European Company to Obtain CE IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing July 8 2014 Sophia Genetics raises Series B round led by Invoke Capital July 1 2014 Stage 3 Phase 2 study of DARPin abicipar pegol previously MP0112 supports progressing to phase III development program June 19 2014 Bind Therapeutics enters nanomedicine collaboration with Swiss drug giant April 10 2014 CeQur Appoints Douglas Lawrence Chief Executive Officer April 8 2014 Epigenetic Cancer Therapy Clears Phase I March 5 2014 Diabetes Care Publishes Data Demonstrating PaQ Insulin Delivery Device Could Help People with Type 2 Diabetes Overcome Barriers to Insulin Adherence and Improve Clinical Outcomes January 8 2014 CeQur to Present at the 32nd Annual J P Morgan Healthcare Conference December 4 2013 Roche and Molecular Partners enter into alliance to develop new cancer treatments October 28 2013 Symetis Announces a Symbolic Milestone the 1000th Patient Implanted with ACURATE TA October 28 2013 French Cost Effectiveness Trial of PneumRx RePneu LVR Coil Fully Enrolled in Record Time September 26 2013 Symetis and Endoluminal Sciences enter into a license agreement to develop 3rd generation TAVI September 24 2013 Data Demonstrating Potential Benefits of Simple Insulin Delivery Device Presented at European Association for the Study of Diabetes Annual Meeting September 19 2013 BIND Therapeutics Announces Pricing of Initial Public Offering September 9 2013 CeQur SA Closes 27 Million Series B Financing August 27 2013 BIND Recognized by the World Economic Forum as a Technology Pioneer August 19 2013 BIND Doses First Patient in a Phase 2 Clinical Study of BIND 014 in Prostate Cancer August 12 2013 BIND Therapeutics Files Registration Statement for Proposed Initial Public Offering August 12 2013 Symetis announces successful first time implantation of i ts ACURATE TA and ACURATE TF TAVI systems in Japan April 3 2013 Symetis ACURATE TA TM Confirms Superior Results February 23 2011 BIND Biosciences named one of MIT s Technology Review 2011 TR50 second year in a row April 13 2010 CeQur SA names Robert O Holla EVP for Regulatory Affairs Former Worldwide VP for Regulatory Affairs at Johnson Johnson Brings Vast Experience in Medical Device Submissions Approvals and GMP Compliance MONTREUX Switzerland April 13 2010 CeQur SA a company focused on the 0development and commercialization of insulin delivery systems to improve the management of type 2 diabetes announced the appointment of Robert O Holla as executive vice president for regulatory affairs effective May 1 O Holla previously spent 33 years at Johnson and Johnson where for the last 18 years he served as worldwide vice president for regulatory affairs While at J J he oversaw numerous regulatory submissions and approvals for medical devices creating strategies that led to the successful approval of novel devices and combination

    Original URL path: http://www.endeavourvision.com/news-n140-c0-s22-CeQur+SA+names+Robert+O%27Holla+EVP+for+.htm (2016-04-25)
    Open archived version from archive

  • Sophia Genetics reaches milestone to become the global leader in precision medicine, connecting over 100 hospitals and laboratories to form the world’s largest clinical genomics community for molecular diagnosis
    institutions within the community use Sophia Genetics cutting edge analytical solution and its advanced machine learning algorithms to analyse the genetic make up of some common cancers and inherited conditions such as such as cystic fibrosis so that clinicians can more accurately diagnose patients at speed and at scale Speaking about this key milestone moment Jurgi Camblong CEO and co founder of Sophia Genetics commented Over the past 18 months Sophia Genetics technology has been able to make precision medicine a reality for healthcare institutions across Europe helping patients benefit from faster and more accurate diagnosis I am thrilled that Sophia Genetics today has been recognised as the global leader in this field and is helping Europe lead the wider healthcare industry in delivering the value and promises associated with personalised medicine The company performed over 20 000 patient analyses in 2015 and expects to quadruple this number in 2016 Users of Sophia DDM include Oxford University Hospitals Hospices Civils de Lyon Val d Hebron Hospital and University Hospital Cologne which leverage Sophia Genetics industry leading genetic analysis technology to provide clinicians the most accurate fast and cost effective means to offer genomic analysis of samples to their patients Jurgi Camblong added Breaking down the information silos in healthcare our technology acted as a real disruptor In a spirit of crowdsourcing and sharing economy Sophia DDM now allows molecular diagnosis information to be used where it is needed most no matter where patients are treated As we see more hospitals and labs embracing DNA Next Generation Sequencing NGS technics I am particularly pleased to see Europe leading the way in the field and I look forward to welcoming more healthcare institutions on to our community platform Since its inception Sophia has built an innovative network of pioneer healthcare institutions all leaders in their countries and eager to accelerate the routine clinical use of genomics data where they matter most first in the clinical diagnosis setting particularly with DNA data resulting from NGS The community now spans 18 European countries from Spain to Poland and places Europe as a leader in precision medicine More countries are expected to join as new hospitals and labs make use of Sophia DDM back Endeavour Vision SA 2006 2016 Terms Conditions The partners have been very supportive of our approach and stepped in to add value when needed I would strongly recommend them as investors Didier Cowling Founder and CEO Kuros Biosurgery AG In preparing for our dual IPOs on the Nasdaq and Neuer Markt it was very important for SCM Microsystems to gain insight and access to the European investment scene This team helped SCM build the foundation for our successful offerings not only with capital but with sound guidance and value added services as well Robert Schneider founder and CEO SCM Microsystems Inc VC is about funding your project but it is more about extending your core team Thus it is about partnering with those who are great to work with and are

    Original URL path: http://www.endeavourvision.com/news-n266-more-Sophia+Genetics+reaches+milestone+to+bec.htm (2016-04-25)
    Open archived version from archive

  • Molecular Partners 1H 2015 Release
    was interested to shift the scope of the agreement to other areas in oncology Molecular Partners did not support the scope shift to avoid potential competition on the internal oncology pipeline Consequently the parties agreed to discontinue the collaboration FINANCIAL HIGHLIGHTS Molecular Partners financial development for the first six months of 2015 was in line with management s expectations and the guidance provided to the capital markets CFO Andreas Emmenegger summarizes the first half year 2015 Our ongoing strong financial position gives us the strategic flexibility to maximize the commercial potential of our proprietary DARPin product candidates by either developing them on our own or selectively entering into new partnerships to unlock the full potential of DARPins Per June 30 2015 the company had a cash position of CHF 176 million and continued to be debt free Moreover Molecular Partners has already collected the announced USD 50 million milestone fees from Allergan in 2H 2015 USD 15 million for the start of phase 3 for abicipar as well as USD 35 million for Allergan s commitment to the broader alliance We are very confident to close the full year 2015 again with a positive net cash flow This is a remarkable achievement for a biotech company in our stage of development and gives us additional cash to invest in our fully owned DARPin programs Andreas Emmenegger concludes Income statement In line with management expectations and guidance In 1H 2015 the company recognized total revenues of CHF 11 2 million 18 less than in the comparable period of the previous year 1H 2014 CHF 13 2 million CHF 7 6 million of total revenues was with Allergan CHF 2 8 million with Roche and CHF 0 8 million with Janssen CHF 7 0 million of total revenues are revenues from technology access and transfer recognized income from discovery alliances with Allergan Roche and Janssen CHF 4 1 million are revenues from R D collaborations deferred revenue recognitions from up front payments as well as FTE payments and CHF 0 1 million are other revenues cost recharges As per June 30 2015 the company had CHF 43 3 million deferred revenues on the balance sheet which is expected to be recognized as revenues as follows CHF 13 3 million in 2H 2015 CHF 13 5 million in 2016 CHF 6 0 million in 2017 CHF 6 0 million in 2018 and CHF 4 5 million in 2019 Overall total operating expenses increased by CHF 3 4 million 23 to CHF 15 1 million 1H 2014 CHF 11 7 million These costs included CHF 2 4 million non cash effective share based compensation and pension costs The two major expense categories were personnel expenses of CHF 9 1 million 60 of total operating expenses and research consumables and costs of CHF 2 9 million 19 of total operating expenses The management team expects operating expenses to increase substantially particularly as the company continues the development of its proprietary product candidates expand the proprietary product pipeline and invest in the DARPin technology Furthermore the management team expects to incur additional costs associated with operating as a public company hiring additional personnel and potentially expanding the facilities As per June 30 2015 the company had 83 FTE s on its payroll thereof 76 1 or 92 in R D and 6 9 FTE s or 8 in G A December 31 2014 74 1 total FTE s June 30 2014 73 2 total FTE s In 1H 2015 the company generated an operating loss of CHF 3 9 million 1H 2014 operating profit of CHF 1 5 million The decline compared to the first half 2014 is in line with expectations of the management team and is a result of reduced accounting revenues and increased R D activities for the benefit of the long term value creation In 1H 2015 Molecular partners incurred a net financial expense of CHF 3 2 million 1H 2014 net financial income of CHF 0 02 million This was mainly driven by unrealized foreign exchange losses of CHF 1 8 million and CHF 1 4 million on the cash balances held in USD and in EUR respectively In 1H 2015 the company incurred a net loss of CHF 7 1 million 1H 2014 net profit of CHF 1 5 million The reduction compared to the previous year is mainly a result of reduced revenues increased R D activities and unrealized foreign exchange losses on the cash balances held in USD and EUR Balance sheet and capital resources Strong position maintained in 2015 Total assets increased by CHF 91 2 million from CHF 102 3 million June 30 2014 to CHF 193 5 million June 30 2015 which is mainly a result of the cash proceeds from the IPO in November 2014 Compared to year end 2014 CHF 194 0 million total assets remained virtually unchanged As a result of the IPO total shareholders equity also increased to CHF 143 0 million June 30 2014 CHF 50 3 million Compared to year end 2014 total shareholder s equity slightly decreased Dec 31 2014 CHF 148 5 million The company continues to be debt free Cash flow statement Strong cash position of CHF 175 6 million per June 30 2015 pre Allergan milestones collected in 2H 2015 In 1H 2015 Molecular Partners incurred a negative net cash flow from operations of CHF 9 3 million while in 1H 2014 the company had generated a positive net cash flow from operations of CHF 3 1 million due to larger collections from partners in 1H 2014 Cash outflow from investing activities went up to CHF 0 4 million 1H 2014 CHF 0 1 million mainly due to increased capital expenditures for laboratory equipment Net cash from financing activities remained virtually unchanged at CHF 0 1 million 1H 2014 zero Overall this produced a net cash reduction of CHF 12 8 million in 1H 2015 1H 2014 net cash increase of CHF 2 9 million

    Original URL path: http://www.endeavourvision.com/news-n265-more-Molecular+Partners+1H+2015+Release.htm (2016-04-25)
    Open archived version from archive



  •